Ad-hoc | 2 August 2007 06:57
Fresenius SE / Half Year Results
Release of an Ad hoc announcement according to § 15 WpHG, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
----------------------------------------------------------------------
First half 2007: Fresenius reports continued growth in sales and earnings
and raises full-year earnings outlook
Group sales increased by 10 % to € 5,592 million in the first half of 2007
(H1 2006: € 5,078 million). Organic sales growth was 7 %. Acquisitions
contributed 10 %, in particular Renal Care Group, which was consolidated as
from the second quarter of 2006. Divestitures reduced sales by 2 %.
Currency translation effects had a negative impact of 5 %. This was mainly
attributable to the average dollar rate depreciating 8 % against the euro
in the first half of 2007 compared to previous year’s period.
Group operating income (EBIT) increased by 20 % in constant currency and by
15 % at actual rates to € 780 million (H1 2006: € 681 million). The Group’s
EBIT margin improved to 13.9 % (H1 2006: 13.4 %).
Group net income also grew strongly by 44 % in constant currency and by 39
% at actual rates to € 195 million (H1 2006: € 140 million, including
one-time expenses of € 16 million).
Earnings per ordinary share were € 1.26 and earnings per preference share
were € 1.27 (H1 2006, adjusted for the February 2007 share split: ordinary
share € 0.91, preference share € 0.92). This represents an increase of 38 %
for both share classes.
Based on the Group’s strong financial results in the first half, Fresenius
raises its earnings outlook for 2007. Net income is now expected to
increase by ~25 % in constant currency. Previously, the Company expected
net income to increase by 20 to 25 %. Group sales are expected to grow by 8
to 10 % in constant currency.
(Financial statements according to US GAAP)
The Management Board
Bad Homburg v.d.H., August 2, 2007
DGAP 02.08.2007
----------------------------------------------------------------------
Language: English
Issuer: Fresenius SE
Else-Kröner-Straße 1
61352 Bad Homburg v.d.H.
Deutschland
Phone: +49 (0)6172 608-2485
Fax: +49 (0)6172 608-2488
E-mail: ir-fre@fresenius.de
Internet: www.fresenius.de
ISIN: DE0005785638, DE0005785604
WKN: 578563, 578560
Indices: MDAX
Listed: Amtlicher Markt in Frankfurt (General Standard), München,
Düsseldorf; Freiverkehr in Berlin, Hamburg, Stuttgart;
Terminbörse EUREX
End of News DGAP News-Service
---------------------------------------------------------------------------